The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II,...

Background: Gait impairment is common in people with Parkinson's disease. There is a lack http://t.co/BXcMimVgiB

via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/BXcMimVgiB